Yanxin Liu
Pengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.
Journal: Frontiers in public health
Published: July 17, 2022
Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database.
Journal: Frontiers in pharmacology
Published: July 09, 2022
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
Journal: Frontiers in pharmacology
Published: April 14, 2022
A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
Journal: Clinical epidemiology
Published: March 30, 2022
Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Journal: Frontiers in pharmacology
Published: January 26, 2022
Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.
Journal: Frontiers in pharmacology
Published: November 19, 2021
Epirubicin potentiates recombinant adeno-associated virus type 2/5-mediated TRAIL expression in fibroblast-like synoviocytes and augments the antiarthritic effects of rAAV2/5-TRAIL.
Journal: Arthritis and rheumatism
Published: December 02, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026